CoChat

Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer

Open access

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 17 of the 98 sources its claims cite were checked for support.

Abstract

Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of cancer-related death. The mainstay of treatment for metastatic colorectal cancer is chemotherapy, but unfortunately, even with recent progress, overall survival is still poor. Colorectal cancer is a heterogeneous disease, and the underlying genetic differences among tumors can define the behavior and prognosis of the disease. Given the limitations of cytotoxic chemotherapy, research has focused on developing targeted therapy based on molecular subtyping. Since the early 2000s, multiple targeted therapies have demonstrated efficacy in treating metastatic colorectal cancer and have received FDA approval. The epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and DNA mismatch repair pathways have demonstrated promising results for targeted therapies. As new gene mutations and proteins involved in the oncogenesis of metastatic colorectal cancer are identified, new targets will continue to emerge. We herein provide a summary of the updated literature regarding targeted therapies for patients with mCRC.

Overview

CoChat Summary

TL;DR

This narrative review summarizes targeted therapy and immunotherapy options for metastatic colorectal cancer by molecular pathway, including EGFR, VEGF, HER2, immune checkpoint, and NTRK targets. It emphasizes molecular profiling, tumor sidedness, MSI status, and HER2/NTRK alterations as determinants of therapy selection, while noting resistance mechanisms and the need for better biomarkers.

Key findings

  • EGFR-directed therapy benefits are limited mainly to left-sided KRAS wild-type tumors; in TAILOR, FOLFOX plus cetuximab improved overall survival versus FOLFOX alone (20.7 vs. 17.8 months), while the EPOC trial found median overall survival of 81.0 months with chemotherapy versus 55.4 months with cetuximab plus chemotherapy in operable liver metastases, leading the authors to advise against cetuximab in that setting.
  • VEGF-pathway agents show survival gains in metastatic colorectal cancer: bevacizumab plus IFL improved median overall survival versus IFL alone (20.3 vs. 15.6 months); aflibercept plus FOLFIRI improved overall survival versus FOLFIRI (13.5 vs. 12.1 months); ramucirumab plus FOLFIRI improved overall survival versus placebo plus FOLFIRI (13.3 vs. 11.7 months); regorafenib improved median overall survival versus placebo (6.4 vs. 5.0 months); and fruquintinib improved overall survival versus placebo in FRESCO (9.3 vs. 6.6 months) and FRESCO-2 (7.4 vs. 4.8 months, p < 0.001).
  • HER2 amplification occurs in approximately 3–5% of colorectal cancers; in MOUNTAINEER, tucatinib plus trastuzumab produced an objective response rate of 38.1%, and in DESTINY-CRC01, trastuzumab deruxtecan produced an objective response rate of 45.3%, median overall survival of 15.5 months, and progression-free survival of 6.9 months.
  • In MSI-high tumors, pembrolizumab improved progression-free survival versus chemotherapy in KEYNOTE-177 (median 16.5 vs. 8.2 months, HR 0.60, p < 0.001), and first-line nivolumab plus ipilimumab in CheckMate 142 produced an objective response rate of 69%, disease control rate of 84%, and 13% complete response rate; atezolizumab added to FOLFOXIRI plus bevacizumab in AtezoTRIBE improved progression-free survival versus control (13.1 vs. 11.5 months, HR 0.69, p = 0.012).

Methods

  • Broad literature review using MEDLINE/PubMed, with search ending 15 December 2023; search terms included “targeted therapy,” “colon cancer,” “colorectal cancer,” and “immunotherapy.”
  • Inclusion prioritized clinical trials related to targeted therapy and immunotherapy for colorectal cancer metastasis; two authors performed initial review, and the senior author made final inclusion determinations.
  • The paper is a narrative review, not a systematic review or meta-analysis.

Limitations

  • Stated limitations: Not stated in the paper.
  • Evident from the text: the review is broad and narrative rather than systematic, with no formal risk-of-bias assessment or quantitative synthesis, and the search ended in December 2023.
  • Evident from the text: many included trials differ in setting, line of therapy, endpoints, and maturity; for example, overall survival data for sotorasib plus panitumumab were not yet available, and several phase 3 trials were ongoing, limiting direct cross-trial comparisons.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cells13030245

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The EGFR pathway demonstrates multiple targets, including the EGFR, RAS, BRAF V600E, and MEK. The figure was adapted from [13].
Figure 1 The EGFR pathway demonstrates multiple targets, including the EGFR, RAS, BRAF V600E, and MEK. The figure was adapted from [13].CC BY · PubMed Central
Figure 2 The VEGF pathway illustrates the mechanism through which the VEGF receptor elicits angiogenesis. The figure was adapted from [44].
Figure 2 The VEGF pathway illustrates the mechanism through which the VEGF receptor elicits angiogenesis. The figure was adapted from [44].CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 80 Not checked · 15 Own results and interpretations

59 more claims · 6 with their cited sources checked

Create a free account to see all 109 claims and to verify the 81 references still open.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 11
  • The quote only partly states this claim. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 89 references

Cited by

See all 139

Metadata

Authors
Underwood, P. W., Ruff, S. M., & Pawlik, T. M.
Affiliations
The Ohio State University Wexner Medical Center (US)
Corresponding author
Pawlik, Timothy M.
Venue
Cells
Publisher
MDPI AG
Published
2024-01-28
Volume
13
Issue
3
Pages
245
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4391314220
Cited by
130
References
89
Citations by year
2026: 56 · 2025: 56 · 2024: 18
FWCI
6.97
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
metastatic colorectal cancer, targeted therapy, immunotherapy, EGFR, vascular endothelial growth factor, DNA mismatch repair, molecular subtyping, tumor heterogeneity, genetic mutations, carcinogenesis, chemotherapy limitations
MeSH terms
Colonic Neoplasms, Humans, Immunotherapy, Rectal Neoplasms, Colorectal Neoplasms, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cells13030245
The paper
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024). Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. Cells. https://doi.org/10.3390/cells13030245

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.